You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

Lepu Biopharma Co., Ltd. (02157)

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics products in China. The company offers HX008, a humanized IgG4 mAb against human PD-1for the treatment of solid tumors and melanoma. It is conducting phase III clinical study of HX008 in combination therapy with irinotecan, and Phase II clinical trials of HX008 for non-small cell lung cancer, triple-negative breast cancer, and